This is Roche Vietnam's largest and most important event to showcase its cutting-edge diagnostic solutions accompanying crucial healthcare trends in Asia Pacific for the next 3-5 years. The event features inspirational and concrete best practices from prestigious hospitals in APAC and Roche Global that highlight key learnings in improving lab performance, clinical practices, and healthcare system efficiency, that impact greatly on patient outcomes as a result.
Over 300 hospital directors, laboratory leaders, healthcare professionals, and associations across the country participated in the event. Roche Innovation Day 2023 is an opportunity for leading healthcare professionals in the region to discuss five critical trends shaping the industry landscape in the coming years, including: patient-centric care, data-driven care, decentralized care, care delivery ecosystem, and value-based healthcare.
In particular, future trends in healthcare will center on improving patient outcomes by empowering them to make informed decisions and participate in their own care, leveraging AI and analytics to provide personalized healthcare solutions, enabling healthcare to be delivered anytime and anywhere through virtual and home models, fostering collaboration and integration among various stakeholders in the health ecosystem, and promoting quality and value of healthcare services by shifting from volume-based payments to payments tied to outcomes.
PhD. Dr. Pham Trung Ha, Chairwoman of HCMC Association of Clinical Biochemistry, said: "Transformation in healthcare, particularly the diagnostics industry, is expected to accelerate at greater speed post COVID-19 and with the emergence of non-transmitted diseases. Staying abreast of the latest healthcare trends is crucial to healthcare professionals who not only provide patient care today but also tomorrow. We are glad to collaborate with Roche Vietnam to address such helpful and timely topics, which, I believe, will contribute greatly to the country’s healthcare development in the near future."
Assoc. Prof. PhD. Dr. Tran Thi Thanh Huong - Vice Director, National Cancer Institute also acknowledged: “Roche Innovation Day is an excellent platform for mutual learning and open exchange among healthcare professionals in Vietnam and the region. It is important for hospitals, associations and enterprises to work together on these trends, because only then can we sustainably shape Vietnam's healthcare for better patient outcomes in the years to come.”
On the same day, Roche unveiled its latest molecular testing system which is a compact new addition to the Roche molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes. The new system is designed to continue to revolutionize how providers care for patients by enabling healthcare professionals to access reliable and accurate testing solutions to quickly determine the best treatment strategies for their patients.
Dr. Qadeer Raza, General Manager of Roche Vietnam, said : “It is our privilege to showcase Roche Global's latest innovations in diagnostics and collaborate with APAC industry experts to introduce major healthcare trends to the country's healthcare professional community. Roche Innovation Day 2023 builds upon our solid commitment to continue investing in the Vietnamese healthcare system, empowering our partners to innovate, driving operational efficiency and result accuracy that significantly improve patient outcomes across the continuum of care."
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.